Business
ODIN: Veterinary focus accelerates commercialization, with improved results and strong equity position
ODIN: Veterinary focus accelerates commercialization, with improved results and strong equity position
About this update from Odinwell Ab
Revenue and operating loss both improved year-over-year as focus shifted to veterinary medicine, with novaQS product nearing market readiness and strong early demand. High equity ratio and ongoing financing initiatives support continued commercialization efforts.Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.